Biotech entity
All 1 tracked stories fall under one category: pharma. Central Drugs Standard Control Organisation (CDSCO) is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. We currently track 1 Biotech story that mention Delhi High Court, all published on March 18, 2026.
Last mentioned: Jul 6, 2026
Entity pulse
Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 1 tracked stories fall under one category: pharma. Central Drugs Standard Control Organisation (CDSCO) is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. We currently track 1 Biotech story that mention Delhi High Court, all published on March 18, 2026. Each carries 2 original sources on average.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 18 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Delhi High Court. Shared-story counts are live from our verified record — not editorial picks.
Contempt Petition Filed
Petitioners allege CDSCO failed to act on the court's previous directions.
Contempt Notice Issued
Justice Sachin Datta seeks a formal response from CDSCO regarding the delay.
Original Court Order
Delhi HC directs CDSCO to examine safety and regulatory concerns of diabetes drugs used for weight management.
The Delhi High Court has initiated contempt proceedings against India's top drug regulator, the CDSCO, for failing to examine safety concerns regarding the off-label use of diabetes medications for weight loss. This judicial escalation highlights growing concerns over the unregulated boom of GLP-1 agonists in the Indian market.
Delhi High Court is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
